Saturday, 31 October 2026European Markets

PHILIPS KON Stock Over 10% Up So Far Today

Loading stream...

(VIANEWS) - Shares of PHILIPS KON (AEX-Index: PHIA.AS) jumped by a staggering 10.67% to €19.19 at 11:06 EST on Monday, following the last session's upward trend. AEX-Index is sliding 0.2% to €760.66, after two sequential sessions in a row of gains. This seems, as yet, a somewhat down trend trading session today.

About PHILIPS KON

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. It has strategic partnership agreements with TriHealth, Prisma Health, and the University Health System of San Antonio to help the health system standardize patient monitoring, drive interoperability, and lay the foundation for enterprise-wide platform; and Oulu University Hospital to deliver advanced image-guided therapy solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, PHILIPS KON has a trailing twelve months EPS of €-1.84.

Volatility

PHILIPS KON's last week, last month's, and last quarter's current intraday variation average was 1.53%, 0.95%, and 1.61%.

PHILIPS KON's highest amplitude of average volatility was 1.53% (last week), 1.85% (last month), and 1.61% (last quarter).

Volume

Today's last reported volume for PHILIPS KON is 3201779 which is 3.99% below its average volume of 3335050.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PHILIPS KON's stock is considered to be oversold (<=20).

More news about PHILIPS KON (PHIA.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com